Aiforia to publish Financial Statements Bulletin 2025 on March 6, 2026

Aiforia Technologies Plc, Press release, February 18, 2026 09:00 a.m. EET

Aiforia will publish its Financial Statements Bulletin for January–December 2025 on Friday, March 6, 2026, at around 9.00 a.m. EET. After publication, the report will be available on the company's website at https://investors.aiforia.com/.

All interested parties are welcome to a virtual webcast event at 10:00 a.m. EET on the result publication day. The event will be chaired by CEO Jukka Tapaninen and will include a review of the company's financial performance and the progress of its strategy during the year.

The event can be followed at https://aiforia.events.inderes.com/q4-2025. Participants can ask questions via the chat function on the video platform.

A recording of the event and the presentation materials will be published after the event on the company's website https://investors.aiforia.com/.

Analysts and investors following the company can also attend on-site at Flik studio in Sanomatalo, Töölönlahdenkatu 2, Helsinki. Please register for the event by Tuesday, March 3, at 4:00 p.m. Helsinki time at the latest by sending an e-mail to ir@aiforia.com.

Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/ 

Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

About Aiforia 
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.

Find out more at www.aiforia.com